.webp)
New research finds hormone therapy with tirzepatide improves weight loss outcomes in postmenopausal women.
A new study carried out by the Mayo Clinic and Wayne State University has shown that a combination of tirzepatide and menopausal hormone therapy can help increase weight loss in women aged over 50 years. The new retrospective study focused on 120 women in their 50s. The results of the new study have shown that women who use a combination of tirzepatide and hormone therapy lose more weight than those who use only tirzepatide, which can help women lose weight in their 50s.
The new study has shown that women who use a combination of tirzepatide and hormone therapy lose 19.2% on average of their original weight over a 15-month period, compared to those who use only tirzepatide, who lose 14% on average. The difference in weight loss between the two groups of women is 5.2%, which is trending in topics such as weight loss strategies for women after menopause and GLP-1 drugs for weight loss in women in their 50s. More women who use a combination of tirzepatide and hormone therapy lose 30% or more of their original weight over 15 months than those who use only tirzepatide.
The lead researcher, Dr. Regina Castaneda, explained, “The significant difference in outcomes justifies further study into the interaction between tirzepatide and hormone therapy.” The senior author, Dr. Maria Daniela Hurtado Andrade, continued, “Hormone therapy may improve sleep and energy levels, helping women maintain lifestyle changes more effectively.”
Prior studies in 2024 found similar benefits with a combination of hormone therapy and semaglutide, another GLP-1 receptor agonist, but this latest research did not examine which hormone therapies were most effective, a factor to be addressed in future studies using a randomized controlled trial format. Researchers are also looking to determine if this combination will help with cardiovascular and metabolic issues.
.webp)
